Retrospective Analysis of Spinal Cord Stimulation on Chronic Non-cancer Pain

Sponsor
The University of Hong Kong (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05411419
Collaborator
(none)
26
1
12
2.2

Study Details

Study Description

Brief Summary

Since 2014, the Queen Mary Hospital, a tertiary teaching hospital in Hong Kong, has commenced the provision of spinal cord stimulation (SCS) services with structured guidelines, standardized protocols and comprehensive pre- and post-operative assessments. It is hoped that the needs of chronic pain patients, especially those who are refractory to conventional medical management, can be better addressed with the introduction of SCS. Hence, through the proposed retrospective study, the investigator aim to systematically evaluate the use of SCS in Queen Mary Hospital, thereby providing evidence with regard to its efficacy and safety for pain management.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Spinal cord stimulation

Detailed Description

As one of the most common health complaints in the world, low back pain (LBP) can affect people across all age groups, with a lifetime prevalence of 84%. In Hong Kong LBP is reported to be the second most prevalent illness due to work and the most common illness made worse by work. LBP can be acute or chronic, with the former lasting less than six weeks and the latter lasting more than twelve weeks. LBP is believed to have an adverse impact on quality of life and functional performance, creating social and economic costs.

Current guidelines on the management of chronic LBP generally recommend the use of conservative treatments, pharmacological agents and/or invasive treatments. Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in pharmacologic therapy, while conservative treatments such as supervised exercise therapy and cognitive behavioural therapy are other possible therapeutic options. If necessary, more invasive treatments including epidural corticosteroids, intra-articular steroid injections and spinal cord stimulation may be considered.

With the advances in neuromodulation in recent decades, spinal cord stimulation (SCS) has become a well-established therapeutic modality for the treatment of chronic pain. Through the delivery of electrical stimulation to the dorsal column of the spinal cord, SCS modulates the pain signals and replaces the pain sensation with tingling paraesthesia for pain relief. Evidence-based guidelines published by the Neuromodulation Appropriateness Consensus Committee (NACC) of the International Neuromodulation Society recommend the use of SCS for a variety of chronic pain conditions, which include failed back surgery syndrome (FBSS), complex regional pain syndrome (CRPS), upper extremity neuropathic pain syndrome, chronic refractory angina and ischemic peripheral neuropathic pain.

Yet the effectiveness of SCS on chronic non-cancer pain management is still unknown in Hong Kong.

Study Design

Study Type:
Observational
Anticipated Enrollment :
26 participants
Observational Model:
Case-Only
Time Perspective:
Retrospective
Official Title:
Spinal Cord Stimulation for the Management of Chronic Non-cancer Pain: a Retrospective Study
Actual Study Start Date :
Jun 1, 2022
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
May 31, 2023

Outcome Measures

Primary Outcome Measures

  1. pain score [At 1 week after implant of spinal cord stimulation]

    Pain score using numerical rating scale (NRS) from 0 to 10, 0 represents no pain, and 10 represents the worst pain.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • all patients underwent SCS for chronic non-cancer pain management between 2014 to 2021 in Queen Mary Hospital
Exclusion Criteria:
  • missing of essential data

Contacts and Locations

Locations

Site City State Country Postal Code
1 The University of Hong Kong Hong Kong Hong Kong

Sponsors and Collaborators

  • The University of Hong Kong

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Dr. Chi-Wai Cheung, Professor, The University of Hong Kong
ClinicalTrials.gov Identifier:
NCT05411419
Other Study ID Numbers:
  • UW22-507
First Posted:
Jun 9, 2022
Last Update Posted:
Jun 14, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 14, 2022